Zerbaxa

Chemical Nameceftolozane/tazobactam
Dosage FormInjection (intravenous; ceftolozane/tazobactam (1 g/0.5 g))
Drug ClassInhibitors
SystemUrinary
CompanyMerck & Co.
Approval Year2014

Indication

  • For the treatment of the following infections caused by designated susceptible microorganisms: 1. Complicated Intra-abdominal Infections, used in combination with metronidazole. 2. Complicated Urinary Tract Infections, including Pyelonephritis.
Last updated on 4/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zerbaxa (ceftolozane/tazobactam) Prescribing Information2014Cubist Pharmaceuticals U.S., Lexington, MA